QALY Bill Clears House But Its Vague Ban Against ‘Similar Measures’ Unlikely To Succeed In Senate

07 Feb 2024

The legislation is a ‘Trojan horse’ designed to undermine the Biden Administration’s policies on cutting drug prices, a leading Democrat claims.

Democrats are wary of Republicans' intentions. • Source: Shutterstock

House Republicans led by Energy and Commerce Committee Chair Cathy McMorris Rodgers, R-OR, succeeded in pushing a bill (HR 485) through the full House along party lines 7 February that would bar using quality-adjusted life years (QALYs) or any “similar measure” as a metric in coverage and payment determinations in federal health care programs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

24 Apr 2025

• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

23 Apr 2025

• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

Kiji CEO On EU HTA Regulation, Hospital Exemption And The Future Of ATMPs

23 Apr 2025

• By Eliza Slawther

Miguel Forte, CEO of Kiji Therapeutics, tells the Pink Sheet why he is confident in the future of gene therapies, despite the global “turmoil” that is impacting investment in the industry and changes to the EU and US regulatory landscapes.

Brazil’s ANVISA Clarifies Registration Procedures For Biologicals

24 Apr 2025

• By Francesca Bruce

Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.